Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in the 2024 Maxim Healthcare Virtual Summit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event will feature a fireside chat with Dennis McGrath, Lucid's Chief Financial Officer, scheduled for Tuesday, October 15, 2024, at 11:30 AM Eastern Time.
Interested parties can attend the virtual fireside chat by visiting the provided link. Following the conference, a recording of the session will be available on Lucid's investor relations website. This participation demonstrates Lucid's commitment to engaging with investors and sharing insights about their cancer prevention diagnostics business.
Details
News Market Reaction – LUCD
The recorded move for LUCD in the trading session of this news was +0.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Event Details:
- Date: Tuesday, October 15, 2024
- Time: 11:30 AM Eastern Time
- Format: Fireside Chat with Dennis McGrath, Lucid's Chief Financial Officer
- Venue: Virtual
For more information about the 2024 Maxim Healthcare Virtual Summit and to attend Lucid's fireside chat, please visit https://m-vest.com/events/healthcare-10152024.
A recording of the fireside chat will be made available on the investor relations section of the Company's website at ir.luciddx.com following the conclusion of the conference.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-302271379.html
SOURCE Lucid Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.